GPCR — Structure Therapeutics Share News
0.000.00%
Last trade - 00:00Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Structure falls as investors await more obesity trial data, says Jefferies
Brief: Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin And Glp-1 Programs For Chronic Weight Management
Structure Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Structure Therapeutics Q2 net loss widens on higher R&D costs
Brief: Structure Therapeutics Inc. Q2 Net Income USD -106.159 Million
Factbox: Race to launch weight-loss pills heats up as smaller players advance
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Structure's experimental obesity pill shows no signs of liver injury
Brief: Structure Therapeutics - Aleniglipron Shows Up To 16.2% Weight Loss Beyond 36 Weeks In Phase 2B Trial
Structure Therapeutics Q1 net loss widens on higher R&D costs
Brief: Structure Therapeutics Inc. Q1 Net Income USD -75.968 Million
Brief: Structure Therapeutics Appoints Matthew Lang, J.D. As Chief Operating Officer And General Counsel
Lilly obesity pill approval creates an opening for Structure's drug, says H.C. Wainwright